Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Total Liabilities (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Total Liabilities data on record, last reported at $50.2 million in Q1 2026.

  • On a quarterly basis, Total Liabilities rose 91.57% to $50.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $50.2 million, a 91.57% increase, with the full-year FY2025 number at $54.9 million, up 30.6% from a year prior.
  • Total Liabilities reached $50.2 million in Q1 2026 per OLMA's latest filing, down from $54.9 million in the prior quarter.
  • Over the last five years, Total Liabilities for OLMA hit a ceiling of $54.9 million in Q4 2025 and a floor of $12.3 million in Q1 2022.
  • A 5-year average of $28.1 million and a median of $26.2 million in 2025 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: soared 133.62% in 2022, then dropped 4.34% in 2025.
  • Tracing OLMA's Total Liabilities over 5 years: stood at $18.1 million in 2022, then increased by 27.36% to $23.0 million in 2023, then surged by 82.28% to $42.0 million in 2024, then surged by 30.6% to $54.9 million in 2025, then fell by 8.57% to $50.2 million in 2026.
  • Business Quant data shows Total Liabilities for OLMA at $50.2 million in Q1 2026, $54.9 million in Q4 2025, and $45.0 million in Q3 2025.